Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Lisa Brents

TitleAssistant Professor
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentPharmacology & Toxicology, College of Medicine
Address5800 W. 10th
Mail Slot # 611
Little Rock AR 72204
Phone501-686-5521
vCardDownload vCard

    Collapse Overview 

    Collapse Research 
    Collapse research activities and funding
    R21DA049585     (BRENTS, LISA KAYE)Aug 1, 2019 - Jul 31, 2021
    NIH
    Use of precision deuteration to determine the contribution of norbuprenorphine to buprenorphine-associated neonatal abstinence syndrome
    Role: Principal Investigator
    R21DA049585     (BRENTS, LISA KAYE)Aug 1, 2019 - Jul 31, 2021
    NIH
    Use of precision deuteration to determine the contribution of norbuprenorphine to buprenorphine-associated neonatal abstinence syndrome
    Role: Principal Investigator
    T32DA022981     (ZIELINSKI, MELISSA J)Jul 1, 2019 - Jun 30, 2024
    NIH/Nat. Inst. on Drug Abuse
    Translational Training in Addiction - Continuation
    Role: Co-Investigator
    KL2 2017-01-Revised     (BRENTS, LISA)Oct 1, 2017 - Mar 31, 2020
    UAMS Intramural Grant (CTSA)
    No FP attached
    Role: Principal Investigator
    KL22017     (BRENTS, LISA)Oct 1, 2017 - Mar 31, 2020
    UAMS Intramural Grant (CTSA)
    No FP attached
    Role: Principal Investigator
    AWD00052450 KL2 2017-01     (BRENTS, LISA K)Oct 1, 2017 - Sep 30, 2018
    UAMS CTSA
    The Metabolic and Pharmacodynamic Profile of Deuterated Buprenorphine
    Role: Principal Investigator
    AWD00052204 FY18 ABI Awards     (BRENTS, LISA K)Jul 1, 2017 - Jun 30, 2018
    UAMS Tobacco
    Fellow-to-Faculty Award
    Role: Principal Investigator
    RPGACH     (BRENTS, LISA K)Jun 26, 2017 - Jul 31, 2019
    UAMS College of Medicine
    RSPGACH 17-DN-10
    Role: Principal Investigator
    AWD00052185 RPGACH     (BRENTS, LISA K)Jun 26, 2017 - Jun 25, 2019
    UAMS College of Medicine
    The Role of Norbuprenorphine in the Development of Neonatal Abstinence Syndrome
    Role: Principal Investigator
    VCR award     (BRENTS, LISA K)Mar 1, 2016 - Jun 30, 2016
    UAMS
    Post Doc Support
    Role: Principal Investigator
    VCRaward     (BRENTS, LISA K)Mar 1, 2016 - Jun 30, 2016
    UAMS
    Post Doc Support
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse additional bibliographic sources
    The links below are provided by the researcher to provide access to external online bibliographies that they keep independently from the Profiles System.
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions. Don't see publications published under other names? Login to add alternative names.
    List All   |   Timeline
    1. Tobacyk J, Brents LK. Response to article - alternative interpretation of "there is reduced immunohistochemical staining of placental aromatase in severe neonatal opioid withdrawal syndrome". J Matern Fetal Neonatal Med. 2023 12; 36(1):2183469. PMID: 36863717.
      View in: PubMed
    2. Tobacyk J, Parks BJ, Salazar P, Coward LU, Berquist MD, Gorman GS, Brents LK. Interaction between buprenorphine and norbuprenorphine in neonatal opioid withdrawal syndrome. Drug Alcohol Depend. 2023 08 01; 249:110832. PMID: 37385117.
      View in: PubMed
    3. Janganati V, Salazar P, Parks BJ, Gorman GS, Prather PL, Peterson EC, Alund AW, Moran JH, Crooks PA, Brents LK. Deuterated buprenorphine retains pharmacodynamic properties of buprenorphine and resists metabolism to the active metabolite norbuprenorphine in rats. Front Pharmacol. 2023; 14:1123261. PMID: 37229250.
      View in: PubMed
    4. Tobacyk J, Parks BJ, Lovelady N, Brents LK. Qualitative content analysis of public responses to an FDA inquiry on the impact of scheduling changes to kratom. Int J Drug Policy. 2022 10; 108:103817. PMID: 35952436.
      View in: PubMed
    5. Kulbeth HJ, Fukuda S, Brents LK. Automated quantification of opioid withdrawal in neonatal rat pups using Ethovision? XT software. Neurotoxicol Teratol. 2021 Mar-Apr; 84:106959. PMID: 33529734.
      View in: PubMed
    6. Griffin BA, Caperton CO, Russell LN, Cabanlong CV, Wilson CD, Urquhart KR, Martins BS, Zita MD, Patton AL, Alund AW, Owens SM, Fantegrossi WE, Moran JH, Brents LK. In Utero Exposure to Norbuprenorphine, a Major Metabolite of Buprenorphine, Induces Fetal Opioid Dependence and Leads to Neonatal Opioid Withdrawal Syndrome. J Pharmacol Exp Ther. 2019 07; 370(1):9-17. PMID: 31028107.
      View in: PubMed
    7. Brents LK, James GA, Cisler JM, Kilts CD. Personality variables modify the relationship between childhood maltreatment history and poor functional outcomes. Psychiatry Res. 2018 10; 268:229-237. PMID: 30064070.
      View in: PubMed
    8. Brents L.K. In: Preedy V.R., editor. Handbook of Cannabis and Related Pathologies. Chapter 17 - Correlates and consequences of prenatal cannabis exposure (PCE): identifying and characterizing vulnerable maternal populations and determining outcomes for exposed offspring. 2017; 160-70.
      View Publication
    9. Brents LK. Marijuana, the Endocannabinoid System and the Female Reproductive System. Yale J Biol Med. 2016 06; 89(2):175-91. PMID: 27354844.
      View in: PubMed
    10. Tai S, Hyatt WS, Gu C, Franks LN, Vasiljevik T, Brents LK, Prather PL, Fantegrossi WE. Repeated administration of phytocannabinoid ?(9)-THC or synthetic cannabinoids JWH-018 and JWH-073 induces tolerance to hypothermia but not locomotor suppression in mice, and reduces CB1 receptor expression and function in a brain region-specific manner. Pharmacol Res. 2015 Dec; 102:22-32. PMID: 26361728.
      View in: PubMed
    11. Brents LK, Tripathi SP, Young J, James GA, Kilts CD. The role of childhood maltreatment in the altered trait and global expression of personality in cocaine addiction. J Psychiatr Res. 2015 May; 64:23-31. PMID: 25805246.
      View in: PubMed
    12. Marshell R, Kearney-Ramos T, Brents LK, Hyatt WS, Tai S, Prather PL, Fantegrossi WE. In vivo effects of synthetic cannabinoids JWH-018 and JWH-073 and phytocannabinoid ?9-THC in mice: inhalation versus intraperitoneal injection. Pharmacol Biochem Behav. 2014 Sep; 124:40-7. PMID: 24857780.
      View in: PubMed
    13. Brents LK, Prather PL. The K2/Spice phenomenon: emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products. Drug Metab Rev. 2014 Feb; 46(1):72-85. PMID: 24063277.
      View in: PubMed
    14. Brents LK, Zimmerman SM, Saffell AR, Prather PL, Fantegrossi WE. Differential drug-drug interactions of the synthetic Cannabinoids JWH-018 and JWH-073: implications for drug abuse liability and pain therapy. J Pharmacol Exp Ther. 2013 Sep; 346(3):350-61. PMID: 23801678.
      View in: PubMed
    15. Rajasekaran M, Brents LK, Franks LN, Moran JH, Prather PL. Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors. Toxicol Appl Pharmacol. 2013 Jun 01; 269(2):100-8. PMID: 23537664.
      View in: PubMed
    16. Madadi NR, Penthala NR, Brents LK, Ford BM, Prather PL, Crooks PA. Evaluation of (Z)-2-((1-benzyl-1H-indol-3-yl)methylene)-quinuclidin-3-one analogues as novel, high affinity ligands for CB1 and CB2 cannabinoid receptors. Bioorg Med Chem Lett. 2013 Apr 01; 23(7):2019-21. PMID: 23466226.
      View in: PubMed
    17. Safe SH, Prather PL, Brents LK, Chadalapaka G, Jutooru I. Unifying mechanisms of action of the anticancer activities of triterpenoids and synthetic analogs. Anticancer Agents Med Chem. 2012 Dec; 12(10):1211-20. PMID: 22583404.
      View in: PubMed
    18. Chimalakonda KC, Seely KA, Bratton SM, Brents LK, Moran CL, Endres GW, James LP, Hollenberg PF, Prather PL, Radominska-Pandya A, Moran JH. Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands. Drug Metab Dispos. 2012 Nov; 40(11):2174-84. PMID: 22904561.
      View in: PubMed
    19. Seely KA, Brents LK, Franks LN, Rajasekaran M, Zimmerman SM, Fantegrossi WE, Prather PL. AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies. Neuropharmacology. 2012 Oct; 63(5):905-15. PMID: 22771770.
      View in: PubMed
    20. Liu X, Jutooru I, Lei P, Kim K, Lee SO, Brents LK, Prather PL, Safe S. Betulinic acid targets YY1 and ErbB2 through cannabinoid receptor-dependent disruption of microRNA-27a:ZBTB10 in breast cancer. Mol Cancer Ther. 2012 Jul; 11(7):1421-31. PMID: 22553354.
      View in: PubMed
    21. Seely KA, Brents LK, Radominska-Pandya A, Endres GW, Keyes GS, Moran JH, Prather PL. A major glucuronidated metabolite of JWH-018 is a neutral antagonist at CB1 receptors. Chem Res Toxicol. 2012 Apr 16; 25(4):825-7. PMID: 22404317.
      View in: PubMed
    22. Brents LK, Gallus-Zawada A, Radominska-Pandya A, Vasiljevik T, Prisinzano TE, Fantegrossi WE, Moran JH, Prather PL. Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity. Biochem Pharmacol. 2012 Apr 01; 83(7):952-61. PMID: 22266354.
      View in: PubMed
    23. Koryakina Y, Jones SM, Cornett LE, Seely K, Brents L, Prather PL, Kofman A, Kurten RC. Effects of the ?-agonist, isoprenaline, on the down-regulation, functional responsiveness and trafficking of ?2-adrenergic receptors with N-terminal polymorphisms. Cell Biol Int. 2012; 36(12):1171-83. PMID: 22938397.
      View in: PubMed
    24. Brents LK, Medina-Bolivar F, Seely KA, Nair V, Bratton SM, Nopo-Olazabal L, Patel RY, Liu H, Doerksen RJ, Prather PL, Radominska-Pandya A. Natural prenylated resveratrol analogs arachidin-1 and -3 demonstrate improved glucuronidation profiles and have affinity for cannabinoid receptors. Xenobiotica. 2012 Feb; 42(2):139-56. PMID: 21970716.
      View in: PubMed
    25. Brents LK, Reichard EE, Zimmerman SM, Moran JH, Fantegrossi WE, Prather PL. Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity. PLoS One. 2011; 6(7):e21917. PMID: 21755008.
      View in: PubMed
    26. Ajmo JM, Bailey LA, Howell MD, Cortez LK, Pennypacker KR, Mehta HN, Morgan D, Gordon MN, Gottschall PE. Abnormal post-translational and extracellular processing of brevican in plaque-bearing mice over-expressing APPsw. J Neurochem. 2010 May; 113(3):784-95. PMID: 20180882.
      View in: PubMed
    Brents's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (172) concept(s)
    _
    Co-Authors Expand Description
    See all (14) people
    _
    Similar People Expand Description
    See all (35) people
    _
    Same Department Expand Description
    Search Department